Bleeding in Patients with Renal Impairment: A Current Perspective

Abstract

Bleeding complications are a frequent and clinically significant problem in patients with chronic kidney disease (CKD), with prevalence increasing as kidney function declines, and in those receiving dialysis. The bleeding tendency in CKD is multifactorial: arising from platelet dysfunction, uremic/inflammatory states, renal anemia, and the common concurrent use of anticoagulants in this population. Together, these mechanisms all contribute to impairment in hemostasis and increased risk of both spontaneous and procedural-hemorrhages. Current bleeding risk assessment tools perform poorly in the CKD population, limiting their utility for guiding clinical decision-making. Emerging evidence suggests that albuminuria, as an independent marker for both renal dysfunction and hemorrhage risk, may improve bleeding risk stratification in this cohort. This review summarizes the pathophysiological mechanisms underlying bleeding in CKD and the impact of dialysis and declining renal function. It also highlights the unmet need for more accurate, CKD-specific bleeding risk assessment tools.

Keywords

chronic kidney disease - end-stage renal disease - anticoagulation - hemorrhage - viscoelastic test

Declaration of GenAI Use

During the writing process of this article, the authors used Grammarly (grammar checker tool) in order to improve language accuracy and clarity. The authors have reviewed and edited the text and take full responsibility for the content of the article.

Publication History

Received: 05 September 2025

Accepted: 21 October 2025

Accepted Manuscript online:
27 October 2025

Article published online:
26 November 2025

• References

• 1 Levey AS, Eckardt KU, Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67 (06) 2089-2100
• 2 Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev 2011; 25 (06) 271-278
• 3 Roderick P, Davies R, Jones C, Feest T, Smith S, Farrington K. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant 2004; 19 (03) 692-701
• 4 Jones A, Swan D, Lisman T, Barnes GD, Thachil J. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost 2024; 22 (02) 323-336
• 5 Murphy D, McCulloch CE, Lin F. et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 2016; 165 (07) 473-481
• 6 Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379 (9811) 165-180
• 7 Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant 2019; 34 (11) 1803-1805
• 8 Francis A, Harhay MN, Ong ACM. et al; American Society of Nephrology, European Renal Association, International Society of Nephrology. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 2024; 20 (07) 473-485
• 9 Sood MM, Bota SE, McArthur E. et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J Kidney Health Dis 2014; 1: 21
• 10 Wasse H, Gillen DL, Ball AM. et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003; 64 (04) 1455-1461
• 11 Wong CX, Odutayo A, Emdin CA, Kinnear NJ, Sun MT. Meta-analysis of anticoagulation use, stroke, thromboembolism, bleeding, and mortality in patients with atrial fibrillation on dialysis. Am J Cardiol 2016; 117 (12) 1934-1941
• 12 Nopp S, Spielvogel CP, Schmaldienst S. et al. Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach. Thromb Haemost 2022;122(9)
• 13 Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19 (01) 135-140
• 14 Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82 (04) 703-713
• 15 Trivedi H, Yang J, Szabo A. Gastrointestinal bleeding in patients on long-term dialysis. J Nephrol 2015; 28 (02) 235-243
• 16 Kuo C-C, Kuo H-W, Lee I-M, Lee C-T, Yang C-Y. The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol 2013; 14: 15
• 17 Liang C-C, Wang S-M, Kuo H-L. et al. Upper gastrointestinal bleeding in patients with CKD. Clin J Am Soc Nephrol 2014; 9 (08) 1354-1359
• 18 Chalasani N, Cotsonis G, Wilcox CM. Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Am J Gastroenterol 1996; 91 (11) 2329-2332
• 19 Molnar AO, Bota SE, Garg AX. et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol 2016; 27 (09) 2825-2832
• 20 Olesen JB, Lip GY, Kamper A-L. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (07) 625-635
• 21 Yang JY, Lee TC, Montez-Rath ME. et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012; 23 (03) 495-506
• 22 Opera omnia. ex typographia remondiniana1764
• 23 McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13 (05) 311-316
• 24 Ocak G, Rookmaaker MB, Algra A. et al; SMART Study Group. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J Thromb Haemost 2018; 16 (01) 65-73
• 25 Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79 (05) 552-559
• 26 Eknoyan G, Brown III CH. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1 (01) 17-23
• 27 Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29 (01) 29-40
• 28 Smith MC, Dunn MJ. Impaired platelet thromboxane production in renal failure. Nephron J 1981; 29 (3-4): 133-137
• 29 Li N, Wallén NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8 (08) 517-523
• 30 Caruana J, Riva N, Vella K, Davenport A, Gatt A. Navigating through the haemostatic paradox in kidney failure: a practical overview. Br J Haematol 2023; 202 (02) 230-247
• 31 Cunha RSD, Santos AF, Barreto FC, Stinghen AEM. How do uremic toxins affect the endothelium?. Toxins (Basel) 2020; 12 (06) 412
• 32 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (05) 579-589
• 33 Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003; 18 (09) 1834-1841
• 34 Mezzano D, Tagle R, Panes O. et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76 (03) 312-321
• 35 Benigni A, Boccardo P, Galbusera M. et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22 (05) 668-676
• 36 Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol 2006; 81 (12) 915-926
• 37 Pluta J, Nicińska B, Grzeszczyk M. et al. Assessment of the hemostatic parameters and platelet function on thromboelastometry and impedance aggregometry in hemodialysis patients qualified for kidney transplantation: preliminary report. Transplant Proc 2016; 48 (05) 1431-1434
• 38 Bloom A, Greaves M, Preston FE, Brown CB. Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 1986; 62 (01) 143-149
• 39 Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel) 2018; 10 (01) 33
• 40 Siqueira MA, Brunini TM, Pereira NR. et al. Increased nitric oxide production in platelets from severe chronic renal failure patients. Can J Physiol Pharmacol 2011; 89 (02) 97-102
• 41 Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron J 1978; 22 (4-6): 347-353
• 42 Horowitz HI. Uremic toxins and platelet function. Arch Intern Med 1970; 126 (05) 823-826
• 43 Gäckler A, Rohn H, Lisman T. et al. Evaluation of hemostasis in patients with end-stage renal disease. PLoS One 2019; 14 (02) e0212237
• 44 Mezzano D, Pais EO, Aranda E. et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60 (05) 1844-1850
• 45 Baaten CCFMJ, Wollenhaupt J, Henning TM. et al. Impaired secondary platelet response in chronic kidney disease as a consequence of prior platelet activation. JACC Basic Transl Sci 2025; 10 (09) 101355
• 46 de Laval P, Mobarrez F, Almquist T, Vassil L, Fellström B, Soveri I. Acute effects of haemodialysis on circulating microparticles. Clin Kidney J 2018; 12 (03) 456-462
• 47 Gao C, Xie R, Yu C. et al. Thrombotic role of blood and endothelial cells in uremia through phosphatidylserine exposure and microparticle release. PLoS One 2015; 10 (11) e0142835
• 48 Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2 (08) 1275-1281
• 49 Schroit AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 1985; 260 (08) 5131-5138
• 50 Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148 (07) 2207-2216
• 51 Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998; 5 (07) 551-562
• 52 Brophy DF, Carl DE, Mohammed BM. et al. Differences in coagulation between hemodialysis and peritoneal dialysis. Perit Dial Int 2014; 34 (01) 33-40
• 53 Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane. Int J Artif Organs 2002; 25 (06) 529-537
• 54 Batalini F, Aleixo GF, Maoz A, Sarosiek S. Haemodialysis-associated thrombocytopenia: interactions among the immune system, membranes and sterilisation methods. BMJ Case Rep 2019; 12 (09) e229594
• 55 Gritters M, Borgdorff P, Grooteman MP. et al. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?. Nephrol Dial Transplant 2008; 23 (09) 2911-2917
• 56 Guo Q, Lou Y, Liu L, Luo P. How can I manage thrombocytopenia in hemodialysis patient? A review. Ther Apher Dial 2020; 24 (04) 352-360
• 57 Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985; 78 (04) 575-580
• 58 Himmelfarb J, Holbrook D, McMonagle E, Ault K. Increased reticulated platelets in dialysis patients. Kidney Int 1997; 51 (03) 834-839
• 59 Sirolli V, Strizzi L, Di Stante S, Robuffo I, Procopio A, Bonomini M. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost 2001; 86 (03) 834-839
• 60 Bonomini M, Stuard S, Carreno MP. et al. Neutrophil reactive oxygen species production during hemodialysis: role of activated platelet adhesion to neutrophils through P-selectin. Nephron J 1997; 75 (04) 402-411
• 61 Cases A, Reverter JC, Escolar G. et al. Platelet activation on hemodialysis: influence of dialysis membranes. Kidney Int Suppl 1993; 41: S217-S220
• 62 Fernandez F, Goudable C, Sie P. et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59 (01) 139-148
• 63 Howard AD, Moore Jr J, Welch PG, Gouge SF. Analysis of the quantitative relationship between anemia and chronic renal failure. Am J Med Sci 1989; 297 (05) 309-313
• 64 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192 (4802) 531-532
• 65 Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost 2019; 17 (02) 271-282
• 66 Roumeliotis S, Mallamaci F, Zoccali C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update. J Clin Med 2020; 9 (08) 2359
• 67 Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57 (05) 946-955
• 68 Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13 (03) 389-397
• 69 Kidney Disease: Improving Global Outcomes (KDIGO). CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. 2013; 3: 82
• 70 Seliger SL, Zhang AD, Weir MR. et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011; 80 (03) 288-294
• 71 Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010; 17 (05) 420-427
• 72 Gaspari F, Viganò G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79 (06) 1788-1797
• 73 Mahady SE, Polekhina G, Woods RL. et al. Association between CKD and major hemorrhage in older persons: data from the aspirin in reducing events in the elderly randomized trial. Kidney Int Rep 2023; 8 (04) 737-745
• 74 Castaldi PA, Rozenberg MC, Stewart JH. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1966; 2 (7454) 66-69
• 75 Carvalho AC. Bleeding in uremia—a clinical challenge. Mass Medical Soc; 1983: 38-39
• 76 Genovesi S, Rossi E, Gallieni M. et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 2015; 30 (03) 491-498
• 77 Shah M, Avgil Tsadok M, Jackevicius CA. et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129 (11) 1196-1203
• 78 Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis. Am Heart J 2017; 184: 37-46
• 79 Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999; 55 (04) 1568-1574
• 80 Pawlak K, Pawlak D, Mysliwiec M. Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007; 18 (05) 467-471
• 81 Borre ED, Goode A, Raitz G. et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018; 118 (12) 2171-2187
• 82 Proietti M, Romiti GF, Vitolo M, Potpara TS, Boriani G, Lip GYH. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J Qual Care Clin Outcomes 2022; 8 (07) 778-786
• 83 Gage BF, Yan Y, Milligan PE. et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (03) 713-719
• 84 Nopp S, Ay C. Bleeding risk assessment in patients with venous thromboembolism. Hamostaseologie 2021; 41 (04) 267-274
• 85 Wattanaruengchai P, Nathisuwan S, Karaketklang K, Wongcharoen W, Phrommintikul A, Lip GYH. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants. Br J Clin Pharmacol 2022; 88 (05) 2203-2212
• 86 Lu HY, Liao KM. Increased risk of deep vein thrombosis in end-stage renal disease patients. BMC Nephrol 2018; 19 (01) 204
• 87 Cheung KL, Zakai NA, Folsom AR. et al. Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2017; 70 (02) 182-190
• 88 Madken M, Mallick R, Rhodes E. et al. Development and validation of a predictive risk algorithm for bleeding in individuals on long-term hemodialysis: an international prospective cohort study (BLEED-HD). Can J Kidney Health Dis 2023 ;10:20543581231169610
• 89 Foster MC, Hwang SJ, Larson MG. et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167 (13) 1386-1392
• 90 Hemmelgarn BR, Manns BJ, Lloyd A. et al; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303 (05) 423-429
• 91 Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332 (7555) 1426
• 92 Khalid A, White D, Sharp M. et al. Investigation of platelet function in patients with chronic kidney disease stages IV-V. Int J Lab Hematol 2021; 43 (06) 1606-1611
• 93 Veninga A, Baaten CCFMJ, De Simone I. et al. Effects of platelet agonists and priming on the formation of platelet populations. Thromb Haemost 2022; 122 (05) 726-738
• 94 Lim HY, Yap ES, Ho P. Global hemostasis testing in chronic kidney disease-are they better predictors of bleeding and thrombosis risk?. Semin Thromb Hemost 2025;
• 95 Huang MJ, Wei RB, Wang Y. et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open 2017; 7 (05) e014294
• 96 Meier K, Saenz DM, Torres GL. et al. Thrombelastography suggests hypercoagulability in patients with renal dysfunction and intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2018; 27 (05) 1350-1356
• 97 Darlington A, Ferreiro JL, Ueno M. et al. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 2011; 106 (01) 67-74
• 98 Abdelmaguid A, Roberts LN, Tugores L. et al. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease. J Thromb Haemost 2022; 20 (04) 845-856
• 99 Brook R, Wang J, Barit D, Ho P, Lim HY. Spontaneous bleeding in chronic kidney disease: global coagulation assays may predict bleeding risk. Res Pract Thromb Haemost 2024; 8 (05) 102520
• 100 Lim HY, Lui B, Tacey M. et al. Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk. Thromb Res 2023; 226: 127-135
• 101 Groene P, Butte J, Thaler S, Görlinger K, Schäfer ST. Modified thromboelastometric tests provide improved sensitivity and specificity to direct oral anticoagulants compared to standard thromboelastometric tests in-vitro. Thromb J 2022; 20 (01) 40
• 102 Oberladstätter D, Voelckel W, Schlimp C. et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia 2021; 76 (03) 373-380
• 103 Hornung P, Khairoun M, Dekker FW. et al. Dosage reduction of low weight heparin in patients with renal dysfunction: effects on anti-Xa levels and clinical outcomes. PLoS One 2020; 15 (10) e0239222
• 104 Brophy DF, Martin EJ, Gehr TW, Carr Jr ME. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004; 44 (02) 270-277
• 105 Takemoto CM, Streiff MB, Shermock KM. et al. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 2013; 139 (04) 450-456
• 106 Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3 (03) 138-153
• 107 Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20 (10) 2223-2233
• 108 Weitz JI, Tankó LB, Floege J. et al; CONVERT Investigators. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med 2024; 30 (02) 435-442